Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor positive lung cancer: The nontrial scenario.

Indian journal of cancer - 1 Jan 2000

Noronha V, Patil V M, Joshi A, Tandon N, Sharma V, Ramaswamy A, More S B, Gaud S, Prabhash K

Abstract excerpt

PURPOSE: The aim of this study was to report the median overall survival (OS) in epidermal growth factor receptor (EGFR) mutation-positive patients who were managed out of a clinical trial. METHODS: Nonsmall cell lung cancer patients harboring activating EGFR mutations who were either ineligible or refused participation in a clinical trial were selected for this analysis. The reason for not participating in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to ErbB Receptors

Share to Kaplan-Meier Estimate

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 29199676
DOI: 10.4103/0019-509X.219583

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor positive lung cancer: The nontrial scenario.PMID 29199676Read ↗

Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.Semantic proximity Read ↗

Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.Semantic proximity Read ↗

Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.Semantic proximity Read ↗

Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.Semantic proximity Read ↗

Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.Semantic proximity Read ↗

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.Semantic proximity Read ↗

Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective study.Semantic proximity Read ↗

Readministration of EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients after initial failure, what affects its efficacy?Semantic proximity Read ↗

Global Transportability of Clinical Trial Outcomes to Real-World Lung Cancer Populations A case Study using Lung-MAP S1400ISemantic proximity Read ↗

Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.Semantic proximity Read ↗

Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.